PH Connect

Why should I refer?

Time lost because of delayed diagnosis cannot be regained

Vascular damage and functional deterioration occur early in PAH, so it is crucial for physicians to act early before more damage is done.1,2 Prompt diagnosis and treatment offers the best chance to delay disease progression, and may improve outcomes in PAH.2

Refer to a PAH expert centre as soon as possible2–4

Due to the complex diagnosis and management of PAH, prescription of PAH-specific therapies has been restricted to clinicians practising at Medicare-approved PAH Designated Centres.5,6 These centres have the required experience, expertise and resources for diagnosing and managing patients with PAH, including:3,5
  • Diagnostic services and expertise with procedures
    • PAH expert centres can promptly perform further necessary tests such as right heart catheterisation (RHC), exercise tolerance, CT scanning/imaging, ventilation/perfusion scan, MRI, etc.
  • PAH nursing and patient support services
  • Access to ongoing medical management via a multidisciplinary team, including relevant allied healthcare professionals
  • PAH management services and clinics, including special access schemes and clinical trials
  • Medicare authorisation to prescribe PAH-specific pharmacological treatment
What to expect after referring your patient to a PAH expert centre

After referral, a shared-care team approach between the referring physician and PAH expert centre is ideal for appropriate ongoing patient management3
References
  1. Strange G, et al. Pulm Circ 2013; 3:89–94.
  2. Lau EMT, et al. Eur Heart J 2011; 32:2489–98.
  3. Galie N, et al. Eur Heart J 2016; 37:67–119.
  4. Frost A, et al. Eur Respir J 2018; in press [https://doi.org/10.1183/13993003.01904-2018].
  5. Department of Human Services. Pulmonary arterial hypertension designated centres. Available at: https://www.humanservices.gov.au/organisations/health-professionals/enablers/pulmonary-arterial-hypertension-designated-centres. Accessed August 2019.
  6. Department of Human Services. Pulmonary hypertension – arterial. Available at: https://www.humanservices.gov.au/organisations/health-professionals/enablers/pulmonary-arterial-hypertension. Accessed August 2019.
Footnotes
CT=computed tomography; MRI=magnetic resonance imaging; PAH=pulmonary arterial hypertension; PH=pulmonary hypertension; RHC=right heart catheterisation.

Suspect.
Detect.
Refer.

Suspect PH Lockup - Suspect, Detect & Refer

What is PAH?

Suspect

Detect

Refer

Janssen-Cilag Pty Ltd, is proud to be a partner of PHSANZ in supporting education & research in the pulmonary hypertension field. PHSANZ is the professional society focused on facilitating research and educating members on the diagnosis and treatment of pulmonary hypertension. Their members include respiratory physicians, cardiologists, rheumatologists, immunologists, nurses and allied health professionals. If you would like more information about PHSANZ, please visit their site on this link.

Janssen is committed to monitoring the safety of our products.  We encourage healthcare professionals to report any suspected adverse events and product complaints for our products to Janssen Medical Information on 1800 226 334 and/or the TGA (at http://www.tga.gov.au/safety/problem-medicine.htm).

Janssen Logo

Janssen-Cilag Pty Ltd
ACN 000 129 975. 1-5 Khartoum Rd Macquarie Park NSW 2113, Australia. Telephone: 1800 226 334 www.janssen.com/australia
Date of Prep: September 2020 CP-140515
Janssen-Cilag Pty, Ltd, all rights reserved.

Do you need guidance on referring to a PAH specialist?

Complete a short questionnaire to receive instant feedback.

START NOW
This content is intended for Australian healthcare professionals. For more information on pulmonary hypertension, please contact your healthcare professional.
Close
Icon/Leaving SiteCreated with Sketch.

Leaving website

The information a reader is about to be referred to may not comply with the Australian regulatory requirements. Further information relevant to the Australian environment is available from the Company or via the Product Information.

OK
Icon/Leaving SiteCreated with Sketch.

Leaving website

The information a reader is about to be referred to may not comply with the Australian regulatory requirements. Further information relevant to the Australian environment is available from the Company or via the Product Information.

OK
Icon/Leaving SiteCreated with Sketch.

Leaving website

The information a reader is about to be referred to may not comply with the Australian regulatory requirements. Further information relevant to the Australian environment is available from the Company or via the Product Information.

OK

World Health Organization functional class (WHO-FC) for patients with PH3,5

This system grades PH severity according to the patient’s functional status, by linking symptoms with activity limitations. WHO-FC remains a powerful predictor of outcomes in patients with PAH.

WHO - FC Description
I
Patients with PH in whom there is no limitation of usual physical activity; ordinary physical activity does not cause increased dyspnoea, fatigue, chest pain, or presyncope.
II
Patients with PH who have mild limitation of physical activity. There is no discomfort at rest, but normal physical activity causes increased dyspnoea, fatigue, chest pain, or presyncope.
III
Patients with PH who have a marked limitation of physical activity. There is no discomfort at rest, but less than ordinary activity causes increased dyspnoea, fatigue, chest pain, or presyncope.
IV
Patients with PH who are unable to perform any physical activity at rest and who may have signs of right ventricular failure. Dyspnoea and/or fatigue may be present at rest, and symptoms are increased by almost any physical activity.
Adapted from McGoon M, et al. 2004.5
Icon/Leaving SiteCreated with Sketch.

Leaving website

The information a reader is about to be referred to may not comply with the Australian regulatory requirements. Further information relevant to the Australian environment is available from the Company or via the Product Information.

OK
Icon/Leaving SiteCreated with Sketch.

Leaving website

The information a reader is about to be referred to may not comply with the Australian regulatory requirements. Further information relevant to the Australian environment is available from the Company or via the Product Information.

OK
Icon/Leaving SiteCreated with Sketch.

Leaving website

The information a reader is about to be referred to may not comply with the Australian regulatory requirements. Further information relevant to the Australian environment is available from the Company or via the Product Information.

OK
Icon/Leaving SiteCreated with Sketch.

Leaving website

The information a reader is about to be referred to may not comply with the Australian regulatory requirements. Further information relevant to the Australian environment is available from the Company or via the Product Information.

OK
Icon/Leaving SiteCreated with Sketch.

Leaving website

The information a reader is about to be referred to may not comply with the Australian regulatory requirements. Further information relevant to the Australian environment is available from the Company or via the Product Information.

OK
Icon/Leaving SiteCreated with Sketch.

Leaving website

The information a reader is about to be referred to may not comply with the Australian regulatory requirements. Further information relevant to the Australian environment is available from the Company or via the Product Information.

OK
Icon/Leaving SiteCreated with Sketch.

Leaving website

The information a reader is about to be referred to may not comply with the Australian regulatory requirements. Further information relevant to the Australian environment is available from the Company or via the Product Information.

OK
Icon/Leaving SiteCreated with Sketch.

Leaving website

The information a reader is about to be referred to may not comply with the Australian regulatory requirements. Further information relevant to the Australian environment is available from the Company or via the Product Information.

OK
Icon/Leaving SiteCreated with Sketch.

Leaving website

The information a reader is about to be referred to may not comply with the Australian regulatory requirements. Further information relevant to the Australian environment is available from the Company or via the Product Information.

OK
Icon/Leaving SiteCreated with Sketch.

Leaving website

The information a reader is about to be referred to may not comply with the Australian regulatory requirements. Further information relevant to the Australian environment is available from the Company or via the Product Information.

OK
Icon/Leaving SiteCreated with Sketch.

Leaving website

The information a reader is about to be referred to may not comply with the Australian regulatory requirements. Further information relevant to the Australian environment is available from the Company or via the Product Information.

OK
This website is intended for Australian healthcare professionals only
I am an Australian healthcare professional
I am a patient/member of the public